Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The interest of the CAPRI study is to confirm the safety and the efficacy of the ENO/TEO/OTO pacing system when used under 1.5 or 3 Tesla MRI environment and in accordance with the MRI solutions guideline.
The purpose of CAPRI study is to confirm the safety and the efficacy of the CE marked MR conditional pacing system composed of the ENO, TEO or OTO pacemaker with VEGA pacing lead(s). Conditions to undergo an MRI scan are provided in the MRI solutions guideline.
The primary objective is to confirm the clinical safety of the ENO/TEO/OTO pacing system when used under 1.5 and 3 Tesla specific MRI conditions without scan exclusion zone.
The study secondary main objectives are aiming to assess the performance of the MR conditional pacing system in the right atrium and ventricle at 1 month following the MRI scan:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1.5 Tesla MRI Scan | Other | Subjects will undergo 1.5T MRI exam |
|
| 3 Tesla MRI Scan | Other | Subjects will undergo 3T MRI exam |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MRI exam | Diagnostic Test | Pacing system safety and stability under MRI scan environment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Freedom from MRI-related complications following the MRI scan of the ENO/TEO/OTO pacing system | An MRI-related complication is defined as a Serious Adverse Event (SAE) that led to death or to an invasive intervention or a Device Deficiency that causes the termination of any significant device function per Clinical Event Committee (CEC) adjudication. The primary endpoint will be assessed independently for each arm of the study (1.5 and 3 Tesla MRI scan). | 1 month post MRI |
| Measure | Description | Time Frame |
|---|---|---|
| Ventricular Pacing Capture Threshold (PCT) stability in the right atrium and ventricle following the MRI scan | Subject's ventricular pacing capture threshold will be measured in Volt (V) at 0.5ms at baseline (at the MRI visit - just before the MRI scan) and at 1 month Post-MRI visit. A success is defined as a PCT increase less than or equal to 0.5V at 0.5ms between the two visits. The secondary endpoints will be assessed independently for each arm of the study (1.5 and 3 Tesla MRI scan). |
Not provided
Inclusion Criteria:
Subjects who meet all the following criteria at the time of inclusion visit may be included:
Already implanted in the left or right pectoral region for at least 6 weeks with:
Implanted pacing system must fulfill the following parameters:
Must agree to undergo a non clinically-indicated MRI scan without intravenous injection and without sedation;
Have reviewed, signed and dated informed consent.
Subjects who meet any of the following criteria are not eligible to be included in the study:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anne RousseauPlasse | Contact | 01 46 01 30 82 | +33 | Anne.RousseauPlasse@crm.microport.com |
| Hanan Fawaz | Contact | 01 46 01 89 01 | +33 | hanan.fawaz@crm.microport.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MicroPort CRM | Recruiting | Clamart | Haut de Seine | 92140 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Dec 20, 2022 | |
| Reset | Oct 20, 2023 | |
| Release | Oct 24, 2023 | |
| Reset | Apr 11, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Dec 20, 2022 | Oct 20, 2023 | |||
| Oct 24, 2023 |
| ID | Term |
|---|---|
| D001919 | Bradycardia |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
This study is an interventional, prospective, multicenter, open label, two arms parallel non-comparative non-randomized study.
Not provided
Not provided
Not provided
Not provided
| 1 month post MRI |
| Atrial Pacing Capture Threshold stability in the right atrium and ventricle following the MRI scan | Subject's atrial pacing capture threshold will be measured in Volt (V) at 0.5ms at Baseline (at the MRI visit - just before the MRI scan) and at 1 month Post-MRI visit. A success is defined as a PCT increase less than or equal to 0.5V at 0.5ms between the two visits. The secondary endpoints will be assessed independently for each arm of the study (1.5 and 3 Tesla MRI scan). | 1 month post MRI |
| Ventricular sensed amplitude stability in the right atrium and ventricle following the MRI scan | Subject's ventricular minimum sensed amplitude will be measured in mV at Baseline (at the MRI visit - just before the MRI scan) and at 1 month Post-MRI visit. A success is defined as 50% or less decrease between the two visits. If subject's ventricular minimum sensed amplitude is less or equal to 4mV at time of baseline, then this subject will not count for this endpoint. The secondary endpoints will be assessed independently for each arm of the study (1.5 and 3 Tesla MRI scan). | 1 month post MRI |
| Atrial sensed amplitude stability in the right atrium and ventricle following the MRI scan | Subject's atrial minimum sensed amplitude will be measured in mV at baseline. A success is defined as 50% or less decrease between the two visits. If subject's atrial minimum sensed amplitude is less or equal to 1mV at time of Baseline (at the MRI visit - just before the MRI scan) and at 1 month Post-MRI visit, then this subject will not count for this endpoint.The secondary endpoints will be assessed independently for each arm of the study (1.5 and 3 Tesla MRI scan). | 1 month post MRI |
| Apr 11, 2024 |
| D013568 |
| Pathological Conditions, Signs and Symptoms |